Related Experiment Video
Updated: Jul 17, 2026
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
[Preclinical studies of the anticancer adenovirus cancerolysin preparation]
Abstract:
The anticancer drug Cancerolysin has been developed, by using the mutant Adel2 variant of human adenovirus serotype 5 designed at the State Research Center of Virology and Biotechnology. Cancerolysin possesses a high degree of replication activity for complementary cells 293 and p53-deficient tumor cells and, at the same time, has significant replication limitations in normal human cells. Preclinical studies of the drug on laboratory animals (mice, rabbits, guinea pigs) have demonstrated its harmlessness and safety. When stored at -40 and -70 degrees C, the drug showed no significant activity throughout the control observational period (1 year).
Insights
The novel anticancer drug Cancerolysin, a modified adenovirus, effectively targets tumor cells while sparing normal cells. Preclinical trials confirm its safety and efficacy for cancer treatment.
Area of Science:
- Oncolytic virology
- Biotechnology
- Gene therapy
Background:
- Development of novel oncolytic viruses for cancer therapy.
- Adenovirus serotype 5 as a potential platform for oncolytic agents.
- Need for cancer therapeutics with tumor-specific replication.
Purpose of the Study:
- To develop and characterize a novel oncolytic adenovirus, Cancerolysin.
- To evaluate the replication selectivity and safety of Cancerolysin.
- To assess the stability of Cancerolysin under storage conditions.
Main Methods:
- Engineering of the Adel2 variant of human adenovirus serotype 5.
- In vitro replication assays in complementary (293) and p53-deficient tumor cells.
- In vitro replication assays in normal human cells.
- Preclinical safety and toxicology studies in mice, rabbits, and guinea pigs.
- Stability testing of Cancerolysin at -40 and -70 degrees C for 1 year.
Main Results:
- Cancerolysin demonstrated high replication activity in complementary 293 cells and p53-deficient tumor cells.
- Cancerolysin exhibited significant replication limitations in normal human cells, indicating tumor selectivity.
- Preclinical studies in laboratory animals showed Cancerolysin to be harmless and safe.
- The drug maintained stability and showed no significant loss of activity after 1 year of storage at -40 and -70 degrees C.
Conclusions:
- Cancerolysin is a promising oncolytic virotherapy agent with demonstrated tumor-specific replication.
- The safety profile in preclinical studies supports its potential for clinical application.
- Cancerolysin exhibits favorable stability, crucial for therapeutic drug development.
